OrbusNeich
 | |
| Company type | Private |
|---|---|
| Industry | Medical Instruments & Supplies |
| Founded | 2005 |
| Headquarters | Hong Kong |
Areas served | Florida, USA (R&D Headquarters), Shenzhen, China (Production & Product Development), Hoevelaken, Netherlands (Production Facility & Marketing and Sales) |
Key people | Teddy Chien (Founder), David Chien (Chairman of the Board), B. Wayne Johnson (CEO) |
| Products | Stent, Balloon |
Number of employees | 500+ |
| Website | www.orbusneich.com |
OrbusNeich is a global company that designs, develops, manufactures and markets medical devices for the treatment of vascular diseases.[1]
In 2013, OrbusNeich received CE mark for the world’s first and only dual therapy stent, the COMBO Dual Therapy Stent. The COMBO Stent features active endothelial progenitor cell (EPC) capture technology, which promotes the accelerated natural healing of the vessel wall after the implantation of a stent.[2]
History
OrbusNeich was founded in 2005, the result of a merger between Orbus Medical Technologies of Fort Lauderdale, Florida, and Hong Kong-headquartered Neich Medical.[citation needed]
Orbus Medical Technologies was founded in 1996. Orbus began as a medical device company and developed the R stent, a bare-metal stent with a novel dual helix design. With the development of the Genous EPC capture technology in 2001, the company created the world’s first pro-healing stent, the Genous Bio-engineered Stent.[citation needed]
Neich International was incorporated in Hong Kong in 1979 as the sole distributor for Cordis in the Asia-Pacific region, including Japan. Neich’s operations and sales were absorbed into Johnson & Johnson with their acquisition of Cordis in 1996. In 1999, Neich Medical re-entered interventional cardiology with investments in and agreements with Orbus Medical Technologies. 2001 saw the opening of manufacturing facility in Shenzhen, China.[3]
At TCT 2011, OrbusNeich’s Combo Dual Therapy Stent, a coronary stent that combines the Genous technology with an antiproliferative, sirolimus drug elution from a biodegradable polymer, was shown to be as effective as a paclitaxel-eluting stent in controlling neointimal hyperplasia.[4] In May 2013, the Combo Dual Therapy Stent received CE Mark approval in Europe. The product has also received regulatory approval in Hong Kong, Malaysia and other selected countries worldwide.[5] Twelve-month results from the randomized REMEDEE trial for the Combo Stent were published in JACC Cardiovascular Interventions.[6]
References
- ^ (January 2010). "OrbusNeich, a company providing stent technology for the future." European Heart Journal.
- ^ (July/August 2014). "First Dual-Therapy Stent Nets CE Mark." Cardiology Today’s Intervention.
- ^ Levin, Stephen (March 2006). "OrbusNeich: Tissue Engineering Meets Coronary Stents." IN VIVO.
- ^ London, Susan (14 November 2011). "Bioengineered, Sirolimus-Eluting Stent Found ‘Safe,’ and ‘Effective.’" Cardiology News.
- ^ http://www.medgadget.com/2013/05/orbusneich-combo-drug-eluting-stent-with-endothelial-progenitor-cell-capture.html
- ^ Haude, M; Lee, SW; Worthley, SG; Silber, S; Verheye, S; Erbs, S; Rosli, MA; Botelho, R; Meredith, I; Sim, KH; Stella, PR; Tan, HC; Whitbourn, R; Thambar, S; Abizaid, A; Koh, TH; Den Heijer, P; Parise, H; Cristea, E; Maehara, A; Mehran, R (2013). "The REMEDEE trial: a randomized comparison of a combination sirolimus-eluting endothelial progenitor cell capture stent with a paclitaxel-eluting stent". JACC Cardiovasc Interv. 6: 334–43. doi:10.1016/j.jcin.2012.10.018. PMID 23523459.